Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients
Hopes Turn To Non-Hospitalized Patients
Ensovibep failed to meet thresholds for continued enrollment in the large NIH Phase III trial, forcing Novartis and Molecular to home in on the early COVID-19 setting instead.
You may also be interested in...
Offering a challenging but blossoming free market model, strong academic institutions and an excellent track record in patents, the Swiss Biotech industry is one to watch.
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.